HNF4A/HNF4G Antibody

What are the primary differences between HNF4A and HNF4G transcription factors?

HNF4A and HNF4G are related transcription factors in the nuclear receptor family with distinct expression patterns and functions:

HNF4A is considered the master regulator of liver-specific gene expression, while HNF4G, despite having similar DNA binding specificity, shows distinct tissue distribution with no expression detected in normal liver . The level of HNF4G is less than 10% that of HNF4A in tissues where both are expressed .

Which applications are HNF4A and HNF4G antibodies most commonly used for?

Based on current research applications, these antibodies are utilized across multiple techniques:

For optimal results, antibody validation through multiple techniques is recommended. Western blot typically shows HNF4A at 50-55 kDa and HNF4G at approximately 46 kDa . When designing experiments, consider using HNF4A/G knockout controls to confirm specificity, as demonstrated in validation studies with A549 cells .

How should researchers optimize ChIP-seq experiments using HNF4A/HNF4G antibodies?

ChIP-seq with HNF4A/HNF4G antibodies requires careful optimization:

• Antibody selection: Choose ChIP-validated antibodies with demonstrated specificity. Multiple studies have successfully used HNF4A antibodies such as ab41898 for ChIP-seq experiments .

• Cross-linking and sonication parameters:

  • Use 1% formaldehyde for 10 minutes at room temperature

  • Optimize sonication to achieve DNA fragments of 200-500 bp

• Experimental controls:

  • Include IgG controls to establish background

  • When possible, use HNF4A/G knockout samples as negative controls

  • Include known target regions as positive controls (e.g., HNF1A promoter for HNF4A ChIP)

• Data analysis considerations:

  • Cross-reference with RNA-seq data to identify functional binding sites

  • Compare binding patterns across different cell types (as HNF4A/G binding can be tissue-specific)

  • Consider developmental timepoints as binding patterns change during differentiation

Recent ChIP-seq studies have identified thousands of HNF4A binding sites (n=16,697 in hepatoblasts, n=2,824 in HepG2 cells) , highlighting the context-dependent nature of HNF4 binding. For HNF4G, research has shown both unique and overlapping binding patterns with HNF4A, particularly in intestinal tissues .

What are the optimal conditions for detecting HNF4A and HNF4G isoforms by Western blot?

Detecting specific HNF4A and HNF4G isoforms requires careful optimization:

• Sample preparation:

  • For nuclear proteins, use nuclear extraction protocols

  • Include protease inhibitors to prevent degradation

  • Load appropriate amounts: 30 μg whole cell lysate, 20 μg cytoplasmic, or 10 μg nuclear extracts

• Gel separation and transfer:

  • Use 8-10% SDS-PAGE for optimal separation of HNF4 isoforms

  • For distinguishing P1 and P2 isoforms of HNF4A, 10% gels with extended run times are recommended

  • Transfer to PVDF membranes using wet transfer systems for best results

• Antibody selection and dilution:

  • For total HNF4A: Most antibodies detect both P1 and P2 isoforms (1:1000 dilution)

  • For isoform-specific detection: Use antibodies that specifically recognize the N-terminal A/B domain

  • For HNF4G: Use 1:500-1:1000 dilution and verify against a positive control sample

• Detection system:

  • HRP-conjugated secondary antibodies with enhanced chemiluminescence

  • For co-detection with other proteins, fluorescent secondaries can be used (as shown in validation images)

Expected band sizes:

• HNF4A: 50-55 kDa (isoform dependent)

• HNF4G1: ~46 kDa

• HNF4G2: ~50 kDa (due to longer N-terminus)

For resolving contradictory results, analyze subcellular fractions separately as demonstrated in published protocols where distinct nuclear localization was confirmed .

How can HNF4A/HNF4G antibodies be used to investigate tissue-specific transcriptional networks?

Advanced research using HNF4A/HNF4G antibodies to investigate transcriptional networks involves:

• Combinatorial ChIP-seq approaches:

  • Perform ChIP-seq for HNF4A, HNF4G, and cofactors (like HNF1A) simultaneously

  • Compare binding sites across multiple tissues (liver, pancreas, intestine)

  • Identify tissue-specific binding patterns through differential peak analysis

• Integration with epigenetic data:

  • Combine HNF4A/G ChIP-seq with histone modification data (H3K27ac, H3K4me3)

  • Analyze chromatin accessibility (ATAC-seq) at HNF4 binding sites

  • Identify tissue-specific enhancers co-bound by HNF4A/G

• Target gene verification methodology:

  • Follow up ChIP-seq with reporter assays using isolated enhancers

  • Perform site-directed mutagenesis of HNF4 binding sites

  • Use CRISPR-Cas9 to delete binding sites and assess gene expression changes

Recent studies have demonstrated how this approach reveals tissue-specific roles. For example, HNF4A and HNF4G cooperatively regulate immune signaling molecules in intestinal epithelial cells through binding to the promoters of Btnl1 and Btnl6 genes, which are crucial for intestinal intraepithelial lymphocyte development . In humans, HNF4A regulates BTNL3 and BTNL8, suggesting evolutionary conservation of this regulatory mechanism .

Importantly, binding patterns differ substantially between tissues. In pancreatic cells, HNF4A regulates metabolism and cell junction assembly, while in liver cells, it governs lipid metabolism and detoxification pathways .

What are the emerging applications of HNF4A/HNF4G antibodies in studying disease mechanisms?

Cutting-edge applications of HNF4A/HNF4G antibodies in disease research involve:

• Diabetes research applications:

  • Analyzing HNF4A variant binding profiles in MODY1 patients

  • Investigating HNF4A binding at T2D-associated loci

  • Examining how disease-associated variants alter HNF4A DNA binding patterns

• Cancer research methodologies:

  • Comparing HNF4A isoform expression between tumor and adjacent tissue

  • Investigating shifts from P1 to P2 HNF4A isoforms in hepatocellular carcinoma

  • Using ChIP-seq to identify altered binding patterns in colon cancer

• Inflammatory bowel disease studies:

  • Examining HNF4A binding in intestinal epithelial cells from IBD patients

  • Investigating how inflammation alters HNF4A/G binding and target gene expression

  • Using tissue microarrays with HNF4A/G antibodies to correlate expression with disease severity

Recent findings using T2D-associated HNF4A variant rs1800961 demonstrated altered DNA-binding affinity leading to upregulation of AKAP1, GAD2, and HOPX genes, suggesting a gain-of-function rather than loss-of-function effect . This highlights how antibody-based approaches can reveal unexpected disease mechanisms.

In inflammatory bowel disease research, reduced expression of HNF4A targets like Btnl1 and Btnl6 was observed after DSS treatment in experimental models, suggesting dysregulation of HNF4A-dependent gene expression during inflammation .

How should researchers address contradictory results when using HNF4A/HNF4G antibodies across different tissues?

When encountering contradictory results with HNF4A/HNF4G antibodies across tissues:

• Tissue-specific expression analysis:

  • Verify baseline expression levels using qPCR before antibody-based experiments

  • Consider different isoform expression patterns (HNF4G1 vs. HNF4G2; P1 vs. P2 HNF4A)

  • Account for developmental stage, as embryonic tissues may express different isoforms than adult tissues

• Methodological approach to resolve contradictions:

  • Use absolute quantification of mRNA to determine relative abundance (as shown in studies comparing Hnf4a and Hnf4g expression)

  • Validate with multiple antibodies targeting different epitopes

  • Include genetic knockout controls whenever possible

  • Verify subcellular localization through fractionation experiments

• Context-dependent regulatory mechanisms:

  • HNF4A and HNF4G may compensate for each other in certain tissues

  • In small intestine, HNF4G appears to functionally substitute when HNF4A is absent

  • In liver, upregulation of Hnf4g mRNA occurs in Hnf4a knockout mice, though still at much lower levels than normal Hnf4a expression

Research has demonstrated that binding patterns differ substantially between tissues—HNF4A binding sites in EndoC-βH1 (pancreatic) cells showed enrichment for cell junction assembly and morphogenesis pathways, while hepatic cells showed different enrichment patterns . These tissue-specific differences must be considered when interpreting seemingly contradictory results.

What control experiments are essential when using HNF4A/HNF4G antibodies to study protein-protein interactions?

Essential controls for HNF4A/HNF4G protein interaction studies include:

• Antibody specificity controls:

  • Use HNF4A/G knockout or knockdown samples as negative controls

  • Perform peptide competition assays to confirm epitope specificity

  • Include isotype control antibodies in co-immunoprecipitation experiments

• Technical validation approaches:

  • Perform reciprocal co-immunoprecipitation (IP with HNF4A, blot for partner; IP with partner, blot for HNF4A)

  • Include input controls (1-5% of starting material)

  • Use mild detergent conditions to preserve weak interactions

  • Consider formaldehyde cross-linking to capture transient interactions

• Specificity confirmation methods:

  • Validate interactions using multiple techniques (co-IP, proximity ligation assay, FRET)

  • Perform domain mapping with truncated constructs to identify interaction interfaces

  • Use in vitro binding assays with purified proteins to confirm direct interactions

Research has shown that HNF4 proteins can form both homodimers and heterodimers between family members. Studies showed that HNF4γ1 repressed HNF4α- and HNF4γ2-dependent transactivation, while HNF4γ2 promoted HNF4α-dependent transactivation . These complex interactions highlight the importance of proper controls when studying HNF4 protein partnerships.

Additionally, consider that HNF4A and HNF4G may compete for binding to the same DNA sites. ChIP-qPCR demonstrated that HNF4G could robustly bind to the promoters of Btnl1 and Btnl6 even in the absence of HNF4A, suggesting potential compensation mechanisms that must be accounted for in experimental design .

How can researchers optimize HNF4A/HNF4G antibodies for multiplex immunofluorescence studies?

For multiplex immunofluorescence studies with HNF4A/HNF4G antibodies:

• Antibody panel design considerations:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • For same-species antibodies, use directly conjugated primary antibodies

  • Verify that epitopes are accessible in fixed tissues (some may require specific retrieval methods)

  • Test each antibody individually before combining

• Optimization methodology:

  • Perform titration series for each antibody (typical range: 1:100-1:1000)

  • Optimize antigen retrieval conditions (TE buffer pH 9.0 recommended for HNF4G)

  • Test different fixation protocols (4% PFA, methanol, or acetone)

  • Establish appropriate blocking conditions to minimize background

• Technical validation approach:

  • Include single-stained controls for spectral unmixing

  • Use biological controls (knockout tissues or siRNA-treated samples)

  • Perform sequential staining for co-localization studies

  • Validate findings with complementary techniques (e.g., PLA, RNAscope)

• Advanced applications:

  • For co-expression studies of HNF4A with target genes, combine with RNA-FISH

  • Use tyramide signal amplification for low-abundance targets

  • Consider tissue clearing techniques for 3D reconstruction of expression patterns

Recent studies have successfully used HNF4A and HNF4G antibodies in immunofluorescence to demonstrate nuclear localization and co-expression with target genes in intestinal epithelial cells . When studying isoform-specific expression, careful validation is particularly important as conventional antibodies may not distinguish between all variants.

How can HNF4A/HNF4G antibodies be used to investigate the role of these factors in maintaining circadian rhythms?

Recent research has revealed HNF4A's role in circadian rhythm regulation, which can be investigated using:

• Temporal ChIP-seq approach:

  • Perform HNF4A ChIP-seq at multiple time points throughout the circadian cycle

  • Analyze rhythmic binding patterns at clock-controlled genes

  • Compare binding patterns between wild-type and clock gene mutants

• Co-immunoprecipitation strategy:

  • Use HNF4A antibodies to immunoprecipitate complexes at different circadian times

  • Identify interactions with core clock components (CLOCK, BMAL1)

  • Validate interactions with reciprocal IPs and mass spectrometry

• Mechanistic investigation methods:

  • Create reporter constructs with HNF4A binding sites from rhythmic genes

  • Perform ChIP-qPCR at circadian gene promoters throughout the day/night cycle

  • Combine with CLOCK/BMAL1 ChIP to identify co-regulated loci

HNF4A has been shown to repress CLOCK-BMAL1 transcriptional activity and is essential for circadian rhythm maintenance and period regulation in liver and colon cells . This emerging area represents an important intersection between metabolism and circadian biology where HNF4A/G antibodies can provide key insights into the temporal dynamics of transcriptional regulation.

What are the best practices for using HNF4A/HNF4G antibodies in single-cell applications?

As single-cell technologies advance, optimizing HNF4A/HNF4G antibody use requires:

• Single-cell protein detection optimization:

  • For flow cytometry, use gentle fixation (0.5-2% PFA) and gradual permeabilization

  • For mass cytometry (CyTOF), metal-conjugated antibodies require validation at single-cell level

  • For imaging mass cytometry, optimize antibody concentration for signal-to-noise in tissue sections

• Multi-omics approaches:

  • For CITE-seq, validate antibodies for TotalSeq™ conjugation

  • For spatial proteomics, test antibodies on control tissue arrays before experimental samples

  • Consider epitope retrieval compatibility with RNA preservation methods

• Validation strategy:

  • Confirm specificity in populations with known HNF4A/G expression patterns

  • Use fluorescence minus one (FMO) controls for accurate gating

  • Validate with orthogonal methods (e.g., single-cell RNA-seq for protein-expressing populations)

• Analysis considerations:

  • Account for cell cycle effects on HNF4A/G expression

  • Consider heterogeneity within nominally similar cell populations

  • Integrate with transcriptomic data to correlate protein and mRNA levels

Single-cell applications can reveal heterogeneity in HNF4A/G expression that is masked in bulk analyses. Flow cytometry has been validated for HNF4G in multiple cell types , providing a foundation for more advanced single-cell applications.